Premedication with a cathepsin C inhibitor alleviates early primary graft dysfunction in mouse recipients after lung transplantation.
Salome R T RehmNatalia F SmirnovaCarmela MorroneJessica GötzfriedAnnette FeuchtingerJohn PedersenBrice KorkmazAli Önder YildirimDieter E JennePublished in: Scientific reports (2019)
Neutrophil serine proteases (NSPs), like proteinase 3 (PR3) and neutrophil elastase (NE) are implicated in ischemia-reperfusion responses after lung transplantation (LTx). Cathepsin C (CatC) acts as the key regulator of NSP maturation during biosynthesis. We hypothesized that CatC inhibitors would reduce vascular breakdown and inflammation during reperfusion in pretreated lung transplant recipients by blocking NSP maturation in the bone marrow. An orthotopic LTx model in mice was used to mimic the induction of an ischemia-reperfusion response after 18 h cold storage of the graft and LTx. Recipient mice were treated subcutaneously with a chemical CatC inhibitor (ICatC) for 10 days prior to LTx. We examined the effect of the ICatC treatment by measuring the gas exchange function of the left lung graft, protein content, neutrophil numbers and NSP activities in the bone marrow 4 h after reperfusion. Pre-operative ICatC treatment of the recipient mice improved early graft function and lead to the disappearance of active NSP protein in the transplanted lung. NSP activities were also substantially reduced in bone marrow neutrophils. Preemptive NSP reduction by CatC inhibition may prove to be a viable and effective approach to reduce immediate ischemia reperfusion responses after LTx.
Keyphrases
- bone marrow
- mesenchymal stem cells
- high fat diet induced
- oxidative stress
- acute myocardial infarction
- extracorporeal membrane oxygenation
- cerebral ischemia
- amino acid
- heart failure
- type diabetes
- coronary artery disease
- room temperature
- binding protein
- insulin resistance
- blood brain barrier
- adipose tissue
- replacement therapy
- percutaneous coronary intervention
- carbon dioxide